Objective: This Finnish nationwide study aimed to refine the clinical phenotype variability and to identify factors that could explain the extensive variability in the clinical severity of the symptoms observed among patients with Unverricht-Lundborg disease (progressive myoclonus epilepsy type 1 [EPM1]) homozygous for the dodecamer expansion mutation in the cystatin B (CSTB) gene.
Unverricht-Lundborg disease (progressive myoclonus epilepsy type 1 [EPM1]) belongs to a group of progressive myoclonus epilepsies. [1] [2] [3] [4] [5] There are studies ranging from singular case/family reports to follow-up of a few dozen patients that have described the clinical manifestations of EPM1. [6] [7] [8] [9] [10] [11] The general consensus was that Finnish patients display a more severe clinical phenotype than patients from the Mediterranean region. 11 The 12-nucleotide dodecamer repeat expansion mutation in the cystatin B (CSTB) gene accounts for approximately 90% of the cases worldwide and 99% of the EPM1 cases in Finland. [12] [13] [14] [15] [16] [17] It was reported that although the expanded alleles in Finnish patients were longer, the actual length did not correlate with clinical disease severity or with age at EPM1 onset. 9, 12, 15, 18, 19 Since Finland has the highest reported incidence of EPM1, 4 we have now collected the largest study population of genetically confirmed EPM1 patients to date. The goal was to characterize in detail the phenotype of our patients by performing a retrospective evaluation of their medical histories and by analyzing the severity of their current symptoms using the Unified Myoclonus Rating Scale (UMRS). Previously, we have shown that compound heterozygous EPM1 patients exhibit a more severe phenotype. 20, 21 We have also reported new radiologic and neurophysiologic findings in EPM1. [22] [23] [24] [25] In this study, we investigated whether there would be associations between the CSTB gene expansion length and the clinical and neurophysiologic characteristics, which might explain the individual variation in the EPM1 phenotype.
METHODS Standard protocol approvals, registrations, and patient consents. The study was carried out in the Kuopio Epilepsy Center, Kuopio University Hospital, jointly with Folkhälsan Institute of Genetics and Neuroscience Center, University of Helsinki. The Ethical Committee of Kuopio University Hospital approved the study protocol and informed consent was obtained from all participants. In the case of adolescent patients (age 12-15 years), the informed consent was provided also by a guardian.
We were able to identify a total of 128 patients with EPM1 and of these 79 participated in the study. Nine patients gave their consent to use only their medical documentation, and 1 patient refused to participate. We were unable to contact 17 patients and 22 patients were known to have died. All 79 patients made a 2-day visit to Kuopio University Hospital, where they underwent clinical, neuropsychological, radiologic, and neurophysiologic evaluation. This study report is restricted to 66 patients with EPM1 homozygous for the expansion mutation in the CSTB gene whose exact number of dodecamer repeats was determined with the high-throughput capillary electrophoresis system.
Clinical assessment of the patients with EPM1. A UMRS
test panel was performed as part of the clinical patient evaluation. UMRS is a quantitative 74-item clinical rating instrument consisting of 8 sections. 26 A patient questionnaire was used to evaluate self-assessed functional disability (score 0-40). Stimulus Sensitivity (maximum score 17), Myoclonus with Action (maximum score 160), and Functional Test (maximum score 28) sections were videorecorded and evaluated with a standard protocol 26 with higher UMRS scores being indicative of more severe myoclonus. All videos were reviewed and scored by the same study physician (J.H.) in order to reduce physician-tophysician variability in scoring. The videos were scored before the genotyping data were obtained, i.e., the scoring physician was unaware of the actual mutation length while conducting the scoring.
The medical history of the patients including age at onset and medications used was collected retrospectively using Kuopio University Hospital or other health institutions' medical records. Additional information regarding patients' social situation and current medication was obtained during the interview at the study visit. Verbal and performance IQ (VIQ and PIQ), performed by an experienced neuropsychologist (M.Ä.), were used for the analysis as measurements of patients' intellectual functioning state.
DNA samples and genotyping. The size of the CSTB dodecamer repeat expansion was determined for all the patients included in this report. Genomic DNA was extracted from peripheral whole blood by using the 5 Prime ArchivePure DNA Blood Base kit (5 PRIME GmbH, Hamburg, Germany). The PCR amplification across the dodecamer repeat expansion was performed as previously described, 27 with 0.8 M proline and 6-FAM dye-labeled reverse primer included in the amplification mix. Amplified fragments were run on a high-throughput capillary electrophoresis system in the presence of GeneScan LIZ-1200 internal size standard (Applied Biosystems, CA, USA) with an ABI 3730xl DNA analyzer (Applied Biosystems). The fragment sizes were determined with GeneMapper 4.0 software (Applied Biosystems).
Navigated transcranial magnetic stimulation. Navigated transcranial magnetic stimulation (nTMS) was utilized to determine the cortical excitability by motor threshold (MT) and silent period (SP) in the primary motor cortex. The method and details of the measurement protocol have been described previously. 22, 28 Out of 66 patients, MTs could not be measured in 8/10 (left and right hemispheres, respectively), because motor evoked potentials could not be elicited even at maximal stimulator output intensity. Similarly, SP from left and right hemisphere, in 18 and 17 patients, respectively, could not be determined as the MTs were not measurable or MT exceeded the 120% MT intensity with the stimulator. The obtained MT and SP values were normally distributed and did not exhibit any interhemispheric differences; therefore the interhemispheric mean values were applied for the analyses.
Statistical analysis. Statistical analyses were performed with IBM (Armonk, NY, USA) SPSS Statistics, version 19. Pearson or Spearman correlation tests, where appropriate, were used to determine correlation between continuous variables. t Test was applied for 2 group comparisons. In order to further explore possible causable effects of the studied parameter on the clinical phenotype heterogeneity, we performed a linear regression analysis, which was used to build prediction models and adjust for confounding factors.
RESULTS
The main demographic and clinical characteristics of 66 genetically confirmed EPM1 patients homozygous for the expansion mutation in the CSTB gene are presented in table 1. On average, the disease started to become manifest at the age of 10 years. In the majority of cases, the first symptoms reported in the medical records were tonic-clonic seizures (48.5%) or myoclonic jerks (30.3%). Twenty-two patients had no history of progressive myoclonus epilepsy or any other epilepsy in the family, 22 patients had a sibling with EPM1, 6 patients reported epilepsy in first-degree relatives, and in 5 cases epilepsy was known in further degree relatives. In 11 cases, the family history was unknown or inconclusive. The study population was very heterogeneous with respect to disease duration (table 1).
In the clinical examination, 36 patients were able to walk, 11 needed to use a wheelchair occasionally, and 19 were completely wheelchair bound. In UMRS testing of action myoclonus, the severity ranged from very mild to severe (table 1) . There was also extensive variability in the sensitivity to different stimuli and motor performance in the Functional Test panel. Accordingly, patients with more severe myoclonus reported more marked disability and more difficulties in everyday activities in the self-assessed disability questionnaire. Episodes of negative myoclonus were observed in 23/66 patients. Mild to severe cerebellar ataxia was seen in all of the patients.
All patients were being treated with antiepileptic drugs (AED) with individually adjusted combinations and dosages (table 2) . Seventeen patients had received phenytoin previously, usually in the early course of the disease, but the history of phenytoin use was unknown in 5 cases because the medical data received from previous treatment centers was incomplete. The longest phenytoin treatment period was 41 months.
In the correlation analysis (table e-1 on the Neurology ® Web site at Neurology.org), higher UMRS scores such as Stimulus Sensitivity, Myoclonus with Action (figure, A), and Functional Test score were associated with earlier age at onset of EPM1. The duration of disease was also associated with higher Myoclonus with Action and Functional Test scores. The associations between the different parameters were further analyzed using linear regression analysis (table 3 ). In the regression models, the Myoclonus with Action score was used as the measurement of myoclonus severity. The regression model included age at onset and disease duration with adjustment for the use of phenytoin and type of disease manifestation (myoclonic jerks or tonic-clonic seizures as the first symptoms). Only age at onset and disease duration were significant independent factors associated with myoclonus severity in the model.
The neuropsychological results showed that higher PIQ, but not VIQ, was significantly associated with later onset of EPM1 (figure, G) and shorter disease duration (table e-1). We also observed that myoclonus severity was associated with a decrease in both VIQ and PIQ (table e-1). Additionally, myoclonus severity was the only significant independent predictor of PIQ in the linear regression analysis (table 3) .
The numbers of dodecamer repeats in the CSTB promoter varied from 38 to 77 (table 1). The size of the longer expansion mutation alleles was associated with an earlier age at onset for EPM1 (table e-1, figure, D). However, this correlation was no longer statistically significant when one patient with longer allele size of only 42 dodecamer repeats and who manifested with the disease rather late (25 years) was excluded from the analysis. We used a mean number of repeats (67) in the longer alleles as a cutpoint for subdividing our study population into 2 groups. In the group analysis, we found that patients with fewer than 67 repeats were more likely to manifest with EPM1 later than those having 68 or more repeats (table 4 ). These subjects also had less severe action myoclonus and higher PIQ compared with those carrying 68 or more dodecamer repeats in the longer allele. However, in the regression analysis, the size of the longer CSTB allele was not independently associated with the clinical phenotype.
In the nTMS results, an earlier disease onset was associated with a prolongation of the SP, but had no effect on MT (table e-1). On the other hand, disease duration was associated with increase in MT. Higher myoclonus severity scores and lower PIQ values were significantly associated with increased cortical MT and prolonged SP (figure, B, C, H, and I). In the regression analysis, SP had a stronger prediction value for myoclonus severity than age at onset (table 3) . Both increased MT and prolonged SP were associated with increased size of the longer CSTB expansion mutation allele (figure, E and F). However, in the regression analysis, SP was significantly associated with the age at onset and the number of AED medications used by the patient, but not the size of the CSTB alleles. In contrast, disease duration and size of the longer CSTB allele remained the best predictors of the MT. DISCUSSION The results of our study allow us to provide some possible explanations for the heterogeneity encountered in patients with EPM1.
Figure
The main correlation results for the clinical, genetic, and navigated transcranial magnetic stimulation results (A-I) Correlation between Myoclonus with Action score and the number of repeats in the longer CSTB expansion mutation allele with progressive myoclonus epilepsy type 1 (EPM1) onset age (years), motor threshold (%), and silent period (ms).
We found that age at disease onset and disease duration were the main factors associated with interindividual variability in myoclonus severity. The average age at EPM1 onset was consistent with most previous observations. 4,10,11 However, these findings have been obtained with group analyses, and therefore, they should be interpreted with caution in the case of an individual patient, since a large degree of variation was observed in the severity of myoclonus even in patients with an identical onset age. The reasons why there are such extensive variations within the same age at onset of EPM1 group await clarification. To some extent, it could be attributed to the disease duration, which ranged widely (4-46 years). It has been previously reported that the disease symptoms progress within the first 5-10 years after onset, but subsequently reach a plateau. 11 Due to our crosssectional study design, we were unable to characterize the disease progression in our study population.
Importantly, we observed a clear linear correlation between the duration of the disease and myoclonus severity. Overall, it is difficult to identify reliably whether patients with an earlier disease onset had a faster and more disabling disease progression or whether their disease had progressed for a longer time until reaching a stable level of disability. It has been postulated previously that phenytoin use may have exerted a major negative impact on myoclonus severity. 29 Accordingly, our older patients were more likely to have received phenytoin treatment in the past. However, in the statistical analyses, previous phenytoin use was not significantly associated with myoclonus severity. Therefore, in our study, the association of disease severity with disease duration could not be attributed to previous phenytoin use.
EPM1 is a recessively inherited genetic disorder caused by 14 mutations in the CSTB gene. [30] [31] [32] It has been previously reported that the number of dodecamer repeats could vary in different alleles of the same patient. 12, 15 Some studies have reported mitotic instability of the expanded alleles, which can result in a different number of dodecamers from generation to generation within the same family. 9, 12, 15, 18, 19, 33 Our patients displayed variable expansion sizes with the longer allele being on average 5 dodecamer repeat units longer than the shorter allele. Previously, it has been hypothesized that the size of the expansion mutation could exert an impact on the EPM1 clinical phenotype. 12, 15 This proposal was based on observations in cases of Friedreich ataxia, a trinucleotide repeat disorder, whose onset correlates with the size of the expansion. However, several previous EPM1 studies have not detected any significant correlation between the size of the CSTB dodecamer expansion mutation and the clinical picture of EPM1, 9, 12, 15 although this may be partially explained by the small number of patients in comparison to our study population. We revealed a significant association between the size of the longer expanded CSTB allele and the age at onset as long as the patient with the smallest longer allele and a rather late disease onset was included in the analysis. However, we did not observe any significant impact of the expansion size on UMRS scores or on IQ values in the correlation analysis. Those patients having 67 or fewer repeats manifested with the disease at a later age and had less severe myoclonus and better PIQ compared with the subjects having 68 or more dodecamer repeats. In the regression model, genetic variation did not seem to have an independent influence on the clinical phenotype. However, the size of the CSTB dodecamer expansion mutation still might have a modulating effect on the clinical EPM1 phenotype. The smallest number of repeats associated with EPM1 has been reported to be 30. 12 The repeat expansion mutation significantly reduces CSTB promoter activity and reduces CSTB protein expression via disruption of the spacing of promoter elements. 34, 35 Correspondingly, CSTB mRNA and protein expressions are significantly reduced in cells taken from patients with EPM1 as compared to controls irrespective of the mutation type. 27 CSTB mRNA expression has also been reported to be reduced in healthy individuals carrying a premutation (12-17 dodecamers). 19, 34 There are, however, no in vitro or in vivo studies investigating whether there is a linear association between the number of repeats and CSTB expression levels or promoter activity.
Previous studies have suggested that certain genes might influence cortical plasticity and excitability processes. 36 We observed that the size of the longer CSTB expansion mutation allele significantly correlated with both MT and SP. Moreover, it was an independent predictor of cortical MT along with disease duration. Previous clinical experience suggests that carbamazepine and phenytoin should be avoided in the treatment of EPM1 due to possible aggravation of myoclonus and myoclonic seizures. 37, 38 Carbamazepine and phenytoin are also known to increase MT. 39 Therefore one could speculate that the harmful effect of these drugs on EPM1 is mediated via a modification of cortical excitability circuits, which are known to be already impaired in EPM1. 22 Since AEDs may alter TMS parameters such as cortical excitability, they also may be hypothesized to influence the results. Accordingly, the number of AEDs used by a patient predicted the SP. However, it has been shown previously that the SP remains unaffected by the individual AEDs used by the subjects in the current study. 40 Thus, this finding may be more likely related to the more severe clinical symptoms experienced by those patients receiving multiple AEDs, since the SP was also predicted by the age at onset of the disease. Furthermore, the SP was a stronger predictor of myoclonus severity in the regression model than the age at onset. It remains debatable whether the increased intracortical inhibition reflected by the SP prolongation leads to an earlier disease onset and a more severe myoclonus, or if an earlier EPM1 onset leads to disturbed neurophysiologic circuits and increased SP.
We observed that earlier EPM1 onset is associated with more severe disease phenotype including more disabling myoclonus and poorer performance in neuropsychological testing. The size of the longer CSTB expansion mutation allele is likely to have a modulating effect on the age at disease manifestation, myoclonus severity, and cortical excitability parameters. Thus, the genetic variation might contribute as a modulator in the pathophysiologic processes of Table 4 Association of the number of repeats in the longer CSTB expansion mutation with the main clinical, neuropsychological, and TMS results EPM1. This finding has a limited prognostic value in the case of an individual patient; however, it provides valuable information for understanding the disease mechanisms of EPM1 and the clinical heterogeneity on the population level.
